Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jul;12(4):161-4.
doi: 10.1007/BF02897985.

Immunotoxicology of beryllium lung disease

Lee S Newman  1
Affiliations

Immunotoxicology of beryllium lung disease

Lee S Newman. Environ Health Prev Med. 2007 Jul.

Abstract

Beryllium induces non-caseating granulomatous inflammation in humans exposed to the metal dust or fumes in both occupational and non-occupational settings. The resulting condition, chronic beryllium disease (CBD), affects principally the lungs, lymphatics, and skin and continues to plague modern industry. Beryllium exerts several important immunotoxic effects, including induction of a beryllium-antigen specific adaptive immune response and the triggering of inflammatory and innate immune responses. Genetic susceptibility plays a role in CBD adaptive immune responses, mainly mediated through single nucleotide polymorphisms in HLA-DP and, to a lesser extent, HLA-DR. The adaptive response is characterized by influx and proliferation of CD4+ central and effector memory T cells expressing Th1 cytokines. Insights into the immunopathogenesis of CBD have implications for the understanding of other immune-mediated granulomatous disorders and for metal antigen behavior.

Keywords: Chronic Beryllium Disease; berylliosis; beryllium; granuloma; metal immunotoxicity.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0140-6736(04)15523-2', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0140-6736(04)15523-2'}, {'type': 'PubMed', 'value': '14962519', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/14962519/'}]}
    2. Infante P, Newman LS. Beryllium exposure and chronic beryllium disease. Lancet 2004;363:415–416. - PubMed
    1. None
    2. Maier LA, Gunn C, Newman LS. Beryllium Disease. In: Rom WN and Markowitz SB editors. Environmental and Occupational Medicine, 4th ed, Philadelphia: Woltersw Kluwer/Lippincott Williams and Wilkins; 2007. pp. 1019–1038.
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '14856439', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/14856439/'}]}
    2. Sterner JH, Eisenbud M. Epidemiology of beryllium intoxication. Arch Industr Hyg Occup Med. 1951;4:123–151. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '14867858', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/14867858/'}]}
    2. Curtis GH. Cutaneous hypersensitivity due to beryllium: a study of thirteen cases. AMA Arch Dermatol Syph. 1951;64: 470–482. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1111/1523-1747.ep12260036', 'is_inner': False, 'url': 'https://doi.org/10.1111/1523-1747.ep12260036'}, {'type': 'PubMed', 'value': '5471892', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/5471892/'}]}
    2. Hanifin JM, Epstein WL, Cline MJ. In vitro studies of granulomatous hypersensitivity to beryllium. J Invest Dermatol. 1970;55:284–288. - PubMed